Market Impact a MarketBrief preview

Hims & Hers (HIMS)

Mentioned in 9 stories across 5 weeks · top score 48 5 3 1

Current view

FDA-exposed names small, single-name

The FDA advisory panel vote to recommend broader pharmacy compounding helps the telehealth/compounding sellers.

From the Market outlook, Jul 30 →

Stories mentioning HIMS

Week 15	FDA Advisory Panel Votes To Recommend Broader Pharmacy Compounding Of Six Peptides	48	medium	called up	no follow-up
Week 3	FDA Proposes Excluding Novo and Lilly Weight-Loss Drugs From Bulk Compounding List	48	medium	called down	played out
Week 15	FDA Panel Votes 8 to 6 To Expand Bpc-157 Compounding, Lifts Hims & Hers 7 Percent	42	medium	called up	not checked
Week 1	FDA peptide review lifts Hims & Hers shares	42	medium	called up	fizzled
Week 15	FDA Advisory Panel Votes 8 to 6 to Recommend Legal Compounding of Unapproved Peptides	34	small	called up	no follow-up
Week 15	FDA Panel Votes to Add BPC-157 to Compounding List, Sending Hims & Hers Shares Up 7%	30	small	called up	not checked
Week 5	Hims & Hers Posts Q1 Loss, Misses Revenue With Weaker EBITDA Outlook	28	small	called down	mixed
Week 8	Hims Closes $1.15 Billion Eucalyptus Acquisition Ahead of Mid-Year 2026 Target	12	small	called mixed	no follow-up
Week 3	Fifth Circuit Pauses FDA Mifepristone Mail and Telehealth Rules	8	no move	called down	not checked